Strive Health has secured $166m in Series C funding to support its next phase of growth and mission for transforming kidney care.

With the new funding, Strive Health plans to strengthen partnerships with payors, health systems, and physicians, expand into new markets, and further develop its clinical value-based care model.

Led by NEA and joined by new investors, including CVS Health Ventures, the funding round will support Strive Health's mission to expand its services to more patients across the US.

The investment will also contribute to the growth and support Strive Health’s current staff and enables it to better serve its existing 80,000 chronic kidney disease and end-stage kidney disease patients across 30 states.

Strive Health CEO and co-founder Chris Riopelle said: “Since our founding, we’ve strongly believed that we must meaningfully change the standard of kidney care so people with kidney disease can have better access to care regardless of their socioeconomic background.

“With the help of our investor partners, this capital raise will propel us further along in our journey to transform kidney care.”

Strive Health has established collaborations with nephrology partners, payors, and health systems, managing more than $2.5bn of annual medical expenditure.

CVS Health Ventures managing partner Vijay Patel said: “Strive's focus on value-based care aligns with CVS Health’s strategy to address the challenges within the US health care system.

“Their differentiated approach has improved health outcomes for patients and driven success for all their customers, including their more than 600 nephrology partners.”